Omidenepag Isopropyl Patent Expiration
Omidenepag Isopropyl is Used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Visiox Pharma Llc
Omidenepag Isopropyl Patents
Given below is the list of patents protecting Omidenepag Isopropyl, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Omlonti | US10179127 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | US10702511 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | US10765750 | Pharmaceutical composition containing pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | US10774072 | Crystal of N-substituted sulfonamide compound | Jun 10, 2035 | Visiox Pharma |
| Omlonti | US11197849 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | US11666563 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | Jul 16, 2039 | Visiox Pharma |
| Omlonti | US11793798 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | US8648097 | Pyridylaminoacetic acid compound | Oct 13, 2029 | Visiox Pharma |
| Omlonti | US8685986 | Medical composition for treatment or prophylaxis of glaucoma | Oct 13, 2029 | Visiox Pharma |
| Omlonti | US9415038 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
| Omlonti | USRE48183 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | Jan 08, 2035 | Visiox Pharma |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳